PRESS RELEASES

Featured post

May 22, 2025

Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025

Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025

Read more »

Featured post

May 12, 2025

Exact Sciences Earns 2025 Great Place To Work^® Certification^™

Exact Sciences Earns 2025 Great Place To Work Certification

Read more »

Featured post

May 01, 2025

Exact Sciences Announces First-Quarter 2025 Results

Exact Sciences Announces First-Quarter 2025 Results

Read more »

August 02, 2022

Exact Sciences and West German Study Group Announce New Study to Validate Detection of Minimal Residual Disease in Early-Stage Breast Cancer Patients
July 08, 2022

Exact Sciences Applauds Proposed CMS Change to Colorectal Cancer Screening Policy
June 01, 2022

Exact Sciences Showcases Breadth of Early Detection and Treatment Guidance Portfolio With Multiple Data Presentations at ASCO 2022
May 19, 2022

Exact Sciences at DDW 2022
May 11, 2022

Updated Guidelines from the American Urological Association Include Genomic Assays, such as the Oncotype DX^® GPS^™ Test, for the First Time in Localized Prostate Cancer Patients
April 28, 2022

Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score^® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients
March 07, 2022

Katie Couric and Cologuard Team Up to Spread Awareness and Urgency for People to Get Screened for Colon Cancer
January 19, 2022

Exact Sciences Presents Data Showing Improved Accuracy of Second-generation Cologuard® Test and Progress Toward an Even Better Colorectal Cancer Screening Solution for Patients
January 10, 2022

Exact Sciences Announces Preliminary Fourth Quarter 2021 Results
January 10, 2022

Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy Response for More Patients
January 10, 2022

Exact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Cancer Testing for More Patients
December 09, 2021

Exact Sciences Commits $500,000 to Urban League Black Business Hub

Choose your country

Patient login

Provider login

Choose your country

PRESS RELEASES

Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025

Exact Sciences Earns 2025 Great Place To Work^® Certification^™

Exact Sciences Announces First-Quarter 2025 Results

Exact Sciences and West German Study Group Announce New Study to Validate Detection of Minimal Residual Disease in Early-Stage Breast Cancer Patients

Exact Sciences Applauds Proposed CMS Change to Colorectal Cancer Screening Policy

Exact Sciences Showcases Breadth of Early Detection and Treatment Guidance Portfolio With Multiple Data Presentations at ASCO 2022

Exact Sciences at DDW 2022

Updated Guidelines from the American Urological Association Include Genomic Assays, such as the Oncotype DX^® GPS^™ Test, for the First Time in Localized Prostate Cancer Patients

Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score^® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients

Katie Couric and Cologuard Team Up to Spread Awareness and Urgency for People to Get Screened for Colon Cancer

Exact Sciences Presents Data Showing Improved Accuracy of Second-generation Cologuard® Test and Progress Toward an Even Better Colorectal Cancer Screening Solution for Patients

Exact Sciences Announces Preliminary Fourth Quarter 2021 Results

Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy Response for More Patients

Exact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Cancer Testing for More Patients

Exact Sciences Commits $500,000 to Urban League Black Business Hub

Need brand logos, photography, and more?

Choose your country

Patient login

Provider login

Choose your country

PRESS RELEASES

Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025

Exact Sciences Earns 2025 Great Place To Work® Certification™

Exact Sciences Announces First-Quarter 2025 Results

Exact Sciences and West German Study Group Announce New Study to Validate Detection of Minimal Residual Disease in Early-Stage Breast Cancer Patients

Exact Sciences Applauds Proposed CMS Change to Colorectal Cancer Screening Policy

Exact Sciences Showcases Breadth of Early Detection and Treatment Guidance Portfolio With Multiple Data Presentations at ASCO 2022

Exact Sciences at DDW 2022

Updated Guidelines from the American Urological Association Include Genomic Assays, such as the Oncotype DX® GPS™ Test, for the First Time in Localized Prostate Cancer Patients

Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients

Katie Couric and Cologuard Team Up to Spread Awareness and Urgency for People to Get Screened for Colon Cancer

Exact Sciences Presents Data Showing Improved Accuracy of Second-generation Cologuard® Test and Progress Toward an Even Better Colorectal Cancer Screening Solution for Patients

Exact Sciences Announces Preliminary Fourth Quarter 2021 Results

Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy Response for More Patients

Exact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Cancer Testing for More Patients

Exact Sciences Commits $500,000 to Urban League Black Business Hub

Need brand logos, photography, and more?

Quick links

Products and services

Science

About

News and events

Exact Sciences Earns 2025 Great Place To Work^® Certification^™

Updated Guidelines from the American Urological Association Include Genomic Assays, such as the Oncotype DX^® GPS^™ Test, for the First Time in Localized Prostate Cancer Patients

Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score^® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients